BJMO - volume 13, issue 1, february 2019
E. Roussel , M. Albersen MD, PhD
Primary urethral cancer is an extremely rare and aggressive malignancy. Due to its rarity and the lack of large prospective trials, no standardised treatment protocols are currently available, and treatment decisions are most often made on a case-to-case basis. We present the case of a 62-year-old male with squamous cell carcinoma of the posterior urethra treated at our institution followed by an in-depth discussion on presentation, diagnosis and treatment of this rare cancer.
(BELG J MED ONCOL 2019;13(1):27–30)
Read more
BJMO - volume 12, issue 6, october 2018
L. Moris , E. Roussel , T. Van den Broeck
Thanks to our improved understanding of the molecular pathogenesis of metastatic renal cell carcinoma, multiple new treatment agents have appeared and extended our therapeutic possibilities. Novel molecular-targeted agents have vastly replaced cytokine therapies but pointed out new challenges in finding the optimal sequence and/or combination in treating metastatic renal cell carcinoma patients. This review focusses on the emerging therapeutic options according to the European Association of Urology guidelines in the rapidly changing renal cell carcinoma landscape.
(BELG J MED ONCOL 2018;12(6):293–300)
Read more
Top
